The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Novel PET Tracer Development Program, 2023Monitoring Glucocerebrosidase Engagement in Parkinson’s Disease
Study Rationale: Glucocerebrosidase is an enzyme that is essential for maintaining healthy lipid metabolism throughout the human body. In Parkinson’s disease (PD), the efficiency of this protein is...
-
Research Grant, 2023Enhancing Access to Meaningful Data: Nebraska Parkinson’s Disease Registry
Study Rationale: Nebraska’s Parkinson’s Disease Registry (NPDR) will roll out a new electronic data collection system, enforce state statutes requiring that physicians participate in reporting...
-
Research Grant, 2023Exploiting a Novel Mechanism for Gene Regulation to Develop Innovative, Targeted Therapies for Parkinson’s Disease
Study Rationale: Neurodegenerative disorders such as Parkinson’s disease (PD) and Alzheimer’s disease (AD) are associated with a variety of disease-causing mutations and genetic variants. In addition...
-
Accelerating the Translation of Parkinson's Disease Therapies, 2023Development of Small Molecule Activators of Nurr1 as Potential Therapeutics for Parkinson's Disease
Study Rationale: Parkonson’s disease (PD) is characterized by neuroinflammation and the death of dopamine-producing neurons. Nurr1 is a protein that regulates the activity of genes to reduce...
-
Translational Pipeline Program, 2023Development of a Small Interfering RNA that Reduces Production of Alpha-synuclein in Parkinson's Disease
Study Rationale: Parkinson’s disease (PD) is associated with a buildup of alpha-synuclein aggregates in the brain. Modulation of alpha-synuclein accumulation has been shown in multiple preclinical...
-
Accelerating Biological Understanding and Therapeutic Translation for Parkinson’s Disease Program, 2023Development and Assessment of LRRK2 Type II Inhibitors as Potential Therapeutics for Parkinson’s Disease
Study Rationale: LRRK2 is one of the best validated drug targets for Parkinson’s disease (PD). The LRRK2 inhibitors currently in development — called Type I inhibitors —bind to the closed, or active...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.